Synergistic platelet inhibition between Omega-3 and acetylsalicylic acid dose titration; an observational study
Bagger, Harald ; Hansson, Mattias ; Kander, Thomas LU
and Schott, Ulf
LU
(2020)
In BMC Complementary Medicine and Therapies
20.
p.1-9
- Abstract
- Background: Omega-3 and acetylsalicylic acid (ASA) are two widely used “over-the-counter” drugs. Previous researchhas shown multiple electrode aggregometry (MEA) can detect ASA and varying Omega-3 platelet inhibiting effects.Synergistic platelet inhibiting effects of ASA and Omega-3 have been found using other methods than MEA. The aimof this study was to investigate the antiplatelet effects of Omega-3, and ASA synergism with MEA.Methods: Ten healthy male volunteers ingested Omega-3 (1260mg/day) for 5 days. MEA was used to analyse plateletfunction before and after Omega-3 intake. Aggregation was initiated using three different agonists and measured asarea under the curve (AUC): adenosine diphosphate (ADP), thrombin receptor activating... (More)
- Background: Omega-3 and acetylsalicylic acid (ASA) are two widely used “over-the-counter” drugs. Previous researchhas shown multiple electrode aggregometry (MEA) can detect ASA and varying Omega-3 platelet inhibiting effects.Synergistic platelet inhibiting effects of ASA and Omega-3 have been found using other methods than MEA. The aimof this study was to investigate the antiplatelet effects of Omega-3, and ASA synergism with MEA.Methods: Ten healthy male volunteers ingested Omega-3 (1260mg/day) for 5 days. MEA was used to analyse plateletfunction before and after Omega-3 intake. Aggregation was initiated using three different agonists and measured asarea under the curve (AUC): adenosine diphosphate (ADP), thrombin receptor activating peptide (TRAP) andarachidonic acid (ASPI). Two concentrations of ASA were dose titrated ex vivo to 2 out of 3 ASPI test cells in order tomeasure synergism between Omega-3 and ASA.Results: Following 5 days Omega-3 intake, ADP, TRAP and ASPI AUC did not change significantly. In vitro ASA beforeOmega-3 intake, reduced ASPI AUC < 30 U, indicating a strong platelet inhibiting effect. Below this AUC level, the 5 daysOmega-3 intake increased ASPI-AUC with the ex vivo added low dose ASA (P = 0.02) and high dose ASA (P = 0.04).Conclusions: No synergism between ASA and Omega-3 was found using the MEA ASPI test. The surprising increase inASPI-AUC following Omega-3 intake and ex vivo ASA suggest that there are methodological issuses with the MEA ASPI test. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/d002174f-0e27-4ad2-968b-b7a24a09f644
- author
- Bagger, Harald
; Hansson, Mattias
; Kander, Thomas
LU
and Schott, Ulf
LU
- organization
- publishing date
- 2020-07-02
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Acetylsalicylic acid, Coagulation, Omega-3
- in
- BMC Complementary Medicine and Therapies
- volume
- 20
- article number
- 204 (2020)
- pages
- 9 pages
- publisher
- BioMed Central (BMC)
- external identifiers
-
- pmid:32615977
- scopus:85100083562
- ISSN
- 2662-7671
- DOI
- 10.1186/s12906-020-02990-9
- language
- English
- LU publication?
- yes
- id
- d002174f-0e27-4ad2-968b-b7a24a09f644
- date added to LUP
- 2020-07-04 08:11:43
- date last changed
- 2022-04-18 23:25:48
@article{d002174f-0e27-4ad2-968b-b7a24a09f644,
abstract = {{Background: Omega-3 and acetylsalicylic acid (ASA) are two widely used “over-the-counter” drugs. Previous researchhas shown multiple electrode aggregometry (MEA) can detect ASA and varying Omega-3 platelet inhibiting effects.Synergistic platelet inhibiting effects of ASA and Omega-3 have been found using other methods than MEA. The aimof this study was to investigate the antiplatelet effects of Omega-3, and ASA synergism with MEA.Methods: Ten healthy male volunteers ingested Omega-3 (1260mg/day) for 5 days. MEA was used to analyse plateletfunction before and after Omega-3 intake. Aggregation was initiated using three different agonists and measured asarea under the curve (AUC): adenosine diphosphate (ADP), thrombin receptor activating peptide (TRAP) andarachidonic acid (ASPI). Two concentrations of ASA were dose titrated ex vivo to 2 out of 3 ASPI test cells in order tomeasure synergism between Omega-3 and ASA.Results: Following 5 days Omega-3 intake, ADP, TRAP and ASPI AUC did not change significantly. In vitro ASA beforeOmega-3 intake, reduced ASPI AUC < 30 U, indicating a strong platelet inhibiting effect. Below this AUC level, the 5 daysOmega-3 intake increased ASPI-AUC with the ex vivo added low dose ASA (P = 0.02) and high dose ASA (P = 0.04).Conclusions: No synergism between ASA and Omega-3 was found using the MEA ASPI test. The surprising increase inASPI-AUC following Omega-3 intake and ex vivo ASA suggest that there are methodological issuses with the MEA ASPI test.}},
author = {{Bagger, Harald and Hansson, Mattias and Kander, Thomas and Schott, Ulf}},
issn = {{2662-7671}},
keywords = {{Acetylsalicylic acid; Coagulation; Omega-3}},
language = {{eng}},
month = {{07}},
pages = {{1--9}},
publisher = {{BioMed Central (BMC)}},
series = {{BMC Complementary Medicine and Therapies}},
title = {{Synergistic platelet inhibition between Omega-3 and acetylsalicylic acid dose titration; an observational study}},
url = {{https://lup.lub.lu.se/search/files/81372799/ASA_OMEGA_3.pdf}},
doi = {{10.1186/s12906-020-02990-9}},
volume = {{20}},
year = {{2020}},
}